Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Material +

Hydreight Reports Record Fiscal 2025 Results as VSDHOne Drives Rapid Growth and Platform Scale

Hydreight Validates Profitability Model But Aggressive 2026 Guidance Looms

By The Northwire Desk — AI Analysis Apr 30, 2026 · 20:56 NURS · 4.22 Hydreight Technologies Inc.
Executive Summary
  • Event: Hydreight Technologies reported Fiscal Year 2025 results on April 30, 2026.
  • Financial Performance:
    • Revenue: $35.4M (up 121% YoY from $16.04M in 2024).
    • Net Income: $1.69M (turnaround from a net loss of $0.41M in 2024).
    • Adjusted EBITDA: $2.5M (up 1,765% YoY from $136K).
    • Operating Leverage: OPEX as % of revenue dropped from 38% to 22%.
  • Operational Metrics:
    • VSDHOne platform licenses surpassed 12,000 by Q1 2026 (up from 11,000+ at year-end 2025).
    • Nurse sign-ups increased ~45% in 2025.
    • National footprint covers all 50 U.S. states.
  • Capital Position:
    • Cash on hand: $15.65M at year-end 2025 (up from $1.19M in 2024).
    • Recent Financing: Completed a $15M bought-deal financing in January 2026.
  • Strategic Moves:
    • Announced a Normal Course Issuer Bid (NCIB) to repurchase up to ~10% of public float in March 2026.
    • Made a strategic investment in Insu Therapeutics ($300,000 total consideration).
Material Impact
  • Positive Validation: The transition from net loss to $1.69M net income is the most significant development. It validates the unit economics of the VSDHOne platform and suggests the business model can sustain profitability at scale.
  • Revenue Growth Confirmation: 121% YoY revenue growth confirms the demand thesis presented in previous guidance updates (Feb 2026). However, the jump from $35.4M (FY2025 actual) to $150M (FY2026 guidance announced Feb 2026) implies a >300% growth rate for the coming year, which is highly aggressive and carries execution risk.
  • Capital Strength: The balance sheet is significantly strengthened with ~$30.7M accessible capital following the January financing. This reduces immediate dilution risk compared to previous quarters where cash burn was a concern.
  • Shareholder Confidence: The NCIB (buyback) signals management believes shares are undervalued, providing a floor for the stock price. However, buybacks funded by working capital can be scrutinized if growth slows.
  • Related Party Concerns: The investment in Insu Therapeutics involves Victory Square Technologies, which controls both Hydreight and Insu. While small ($300k), it highlights potential conflicts of interest or capital allocation to related entities rather than core operations.
NURS · Price
Company Overview
  • Company: Hydreight Technologies Inc. operates a national digital health and pharmacy infrastructure platform in the U.S.
  • Flagship Project: VSDHOne Platform. A technology solution enabling brands to launch direct-to-consumer healthcare services across all 50 states compliantly. It integrates telehealth, prescribing, and pharmacy fulfillment.
  • Development Status: Scaled to >12,000 licenses by Q1 2026. Covers all 50 U.S. states. Focus has shifted from initial rollout to profitability and margin expansion (OPEX % of revenue dropped to 22%).
Read the original news release →

More from Hydreight Technologies Inc.

Jun 01, 2026 · 21:32

Hydreight's Q1 EBITDA Margin Expansion Validates Operating Leverage, But Valuation Premium Demands Flawless Execution

Earnings May 01, 2026 · 00:14

Victory Square Technologies Inc.

Earnings Mar 13, 2026 · 18:43

Hydreight closes acquisition of 800,000 Insu units

M&A / Property Mar 13, 2026 · 16:15

Hydreight Technologies Closes Strategic Investment in Insu Therapeutics

Financings Mar 09, 2026 · 08:00

Hydreight Announces Normal Course Issuer Bid

Other Mar 05, 2026 · 17:42

Hydreight invests $300,000 in Insu Therapeutics

M&A / Property